Europe Approves Orkambi® The European Commission has granted Marketing Authorization for Orkambi® (lumacaftor/ivacaftor), for cystic fibrosis …

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the …

Prohost Letter #387 Topic of the Week DUCHENNE MUSCULAR DYSTROPHY Which Firms Will Get It Right …

– Shire to Acquire Dyax for $5.9million and some possible extras. – Angioedema market has treatments …

Another Durable Botulinum Toxin with Many Advantages REVANCE THERAPEUTICS As per its self- described profile, Revance …

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious …

Prohost Letter #385 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies The Top-Tier …

Incyte (INCY) and Merck (MRK) announced the expansion of their ongoing clinical collaboration to include a Phase …

Prohost Letter #384 The Assassination of the Biotech Sector The Market (Part 2) On Friday September 18, …

Exelixis (EXEL) announced positive results from the METEOR Phase 3 Pivotal Trial of Cabozantinib in advanced …